xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06002126</url>
    </required_header>
    <id_info>
      <org_study_id>23-02025683</org_study_id>
      <secondary_id>U54CA242639</secondary_id>
      <nct_id>NCT06002126</nct_id>
    </id_info>
    <brief_title>Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries</brief_title>
    <official_title>Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Weill Medical College of Cornell University</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>National Cancer Institute (NCI)</agency>
        <agency_class>NIH</agency_class>
      </collaborator>
      <collaborator>
        <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>University of Sao Paulo</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Mexican National Institute of Public Health</agency>
        <agency_class>Other</agency_class>
      </collaborator>
      <collaborator>
        <agency>Rutgers University</agency>
        <agency_class>Other</agency_class>
      </collaborator>
    </sponsors>
    <source>Weill Medical College of Cornell University</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        Cervical cancer is a relatively common cancer among women living with human immunodeficiency&#xD;
        virus (HIV). This study will test women for human papillomavirus (HPV) infection of the&#xD;
        cervix. The main purpose of this study is to determine the best way to test for damaged areas&#xD;
        of the cervix. Damaged areas of the cervix should be treated and removed to prevent cancer of&#xD;
        the cervix.&#xD;
  &#xD;
        Women in this study will be seen once, twice or three times in a year. Women will provide&#xD;
        several samples related to screening for cervical cancer including a swab of the cervix, a&#xD;
        self-collected swab of the vagina and urine. Women will have a detailed examination of the&#xD;
        cervix called colposcopy and have a few biopsies, or small pinches of the cervix, to look for&#xD;
        areas at risk for turning into cancer. If HPV of the cervix is found but treatment of the&#xD;
        cervix is not indicated, women will return in 6 months and in 12 months to repeat these&#xD;
        tests. Most women will only need 1 visit. Women found to have damaged areas of the cervix at&#xD;
        risk for turning into cancer will be referred for treatment.&#xD;
  &#xD;
        This protocol will compare different tests to understand the best test to identify women at&#xD;
        risk for cervical cancer.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The overall goal of this research is to develop a point of care high-risk HPV (hrHPV) test&#xD;
        and molecular testing that optimizes specificity to detect high-grade squamous&#xD;
        intraepithelial lesions (HSIL), specifically cervical intraepithelial neoplasia of grade 2 or&#xD;
        more (CIN 2+), in women living with HIV (WHIV) in Latin America while maintaining high test&#xD;
        sensitivity. To accomplish this goal, the protocol will optimize cervical screening by&#xD;
        modifying the cycle threshold/genotype interpretation of Xpert HPV assay output. In a&#xD;
        secondary manner, the protocol will also evaluate whether triage with HPV/host DNA&#xD;
        methylation improves the specificity of Xpert alone.&#xD;
  &#xD;
        The hypotheses for this protocol includes:&#xD;
  &#xD;
        • The Xpert HPV test can be optimized for HSIL detection (CIN2+) in WHIV to significantly&#xD;
        improve test specificity, when compared to unmodified test output using manufacturer&#xD;
        guidelines.&#xD;
  &#xD;
        To evaluate this hypothesis, the protocol will enroll 1000 cisgender women or transgender men&#xD;
        age 25-65 years living with HIV who are undergoing routine cervical cancer screening. These&#xD;
        individuals will be recruited from affiliated clinical sites of the National Institute of&#xD;
        Public Health in Cuernavaca, Mexico and University of São Paulo, Brazil. Participants will&#xD;
        provide a first void urine sample and will be instructed how to self-collect a vaginal swab.&#xD;
        An oral gargle specimen will be collected for HPV testing, HPV methylation, and Epstein-Bar&#xD;
        Virus (EBV) co-infection. They will receive a baseline questionnaire about risk factors for&#xD;
        HPV and cervical cancer, and provide a blood specimen for CD4 count, plasma viral load, DNA&#xD;
        methylation of biological aging, circulating tumor HPV DNA (ctHPVDNA) analysis, and stored&#xD;
        sera. Next, a provider will collect an anal swab. Then the participant will undergo a&#xD;
        speculum exam and a provider will collect a cervical cytobroom sample for cytology and HPV&#xD;
        testing followed by a swab for stored specimens. Finally, acetic acid will be applied&#xD;
        followed by a digital image of the cervix. Then at least two cervical biopsies will be&#xD;
        obtained.&#xD;
  &#xD;
        Material from one provider-collected cervical swab will undergo cervical cytology assessment&#xD;
        using Bethesda Criteria. Cervical histology results from the collected biopsies will be&#xD;
        interpreted according to the Lower Anogenital Squamous Terminology (LAST). HSIL will be&#xD;
        defined as CIN 2 with diffuse p16 staining, CIN 2-3, or CIN 3. Women diagnosed with HSIL will&#xD;
        be treated according to local standards. The local histology result will be used for the&#xD;
        management of participants. Any lesions suspicious for invasive cancer will be referred to&#xD;
        the appropriate specialist. Women with HSIL on cytology, but no HSIL on histology will be&#xD;
        treated according to the local standard. The management options include repeat colposcopy,&#xD;
        endocervical curettage, or a diagnostic loop electro-excision procedure. Similarly, women&#xD;
        with a Type 3 transformation zone should have endocervical curettage and be managed according&#xD;
        to local standards. After local pathology review, all histology specimens will be shipped&#xD;
        centrally for Histology Endpoint Adjudication; these adjudicated histology results will be&#xD;
        used for reporting research findings. The details of this process will be in the Manual of&#xD;
        Procedures. Discordance between the local and central pathology review will be adjudicated&#xD;
        with a second central pathologist. The final histology result will be sent back to the local&#xD;
        site and provided to the participant and their providers. Women found to have vulvar, vaginal&#xD;
        or perianal lesions suspicious for HSIL will be referred for appropriate evaluation.&#xD;
  &#xD;
        The self-collected vaginal swab and material from the provider-collected cytobroom sample&#xD;
        will be tested for HPV using Xpert HPV. Xpert testing of self- and provider-collected samples&#xD;
        will be conducted locally (at the point of care) in Brazil and Mexico. Remaining material&#xD;
        from the vaginal and cervical samples will be shipped to Dr. Villa's lab in Brazil to allow&#xD;
        for S5 methylation testing of any WHIV with hrHPV detected. Residual samples, as well as the&#xD;
        collected urine, will be stored in Dr. Villa's lab for future studies.&#xD;
  &#xD;
        Women with hrHPV detected on a provider-collected cervical sample using a locally available&#xD;
        and approved test, but who were negative for HSIL as determined by cervical biopsy, will be&#xD;
        asked to return for a follow-up study visit at 6-month to receive the same procedures&#xD;
        described above (with the exception of blood draws). If at the 6-month follow-up visit WHIV&#xD;
        continue to have detection of hrHPV, but are HSIL negative by biopsy, they will be asked to&#xD;
        return for an additional follow-up study visit 6 months later (12-months post-baseline) to&#xD;
        receive the same procedures. We estimate that approximately 40% of the population will have&#xD;
        hrHPV detected and may need to return for a follow-up visit; and 7% will be HSIL+ and&#xD;
        referred for treatment.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">August 2, 2023</start_date>
    <completion_date type="Anticipated">November 1, 2025</completion_date>
    <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
    <phase>N/A</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>N/A</allocation>
      <intervention_model>Single Group Assignment</intervention_model>
      <primary_purpose>Diagnostic</primary_purpose>
      <masking>None (Open Label)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Number of participants with cervical HSIL or invasive cancer on histology at baseline</measure>
      <time_frame>Baseline</time_frame>
      <description>Cervical HSIL is defined as cervical intraepithelial neoplasia (CIN) 2 with p16 staining, CIN2-3, or CIN3) or squamous cell carcinoma from histology of cervical biopsies</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Number of participants with hrHPV at baseline who are found to have cervical HSIL or invasive cancer on histology at months 6 or 12</measure>
      <time_frame>Month 6 or month 12</time_frame>
      <description>Cervical HSIL is defined as cervical intraepithelial neoplasia (CIN) 2 with p16 staining, CIN2-3, or CIN3) or squamous cell carcinoma from histology of cervical biopsies.&#xD;
  Only those subjects that had detection of hrHPV in cervical or vaginal specimens at the baseline or 6 month visit will be included in the count.</description>
    </secondary_outcome>
    <number_of_arms>1</number_of_arms>
    <enrollment type="Anticipated">1000</enrollment>
    <condition>Cervix Cancer</condition>
    <condition>HPV Infection</condition>
    <condition>Cervical High Grade Squamous Intraepithelial Lesion</condition>
    <condition>HIV Infections</condition>
    <arm_group>
      <arm_group_label>Cervical cancer screening (single arm)</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>Women will be screened for cervical cancer with HPV testing that provides extended genotyping and DNA quantification. Women will also provide other samples for cervical cancer screening tests. Women will under cervical biopsies.</description>
    </arm_group>
    <intervention>
      <intervention_type>Diagnostic Test</intervention_type>
      <intervention_name>Xpert HPV</intervention_name>
      <description>The Cepheid Xpert HPV Assay (Xpert HPV) is a qualitative, real-time polymerase chain reaction (PCR) assay for the detection of hrHPV DNA. The assay is formatted in a single-use, Xpert HPV test cartridge and is run on the Cepheid Xpert® System, a multi-analyte, random access, molecular-diagnostic platform ranging in capacity from 1 to 80 test processing modules. Importantly, a single hrHPV DNA test can be completed in one hour, permitting same-day screening and diagnosis (e.g. colposcopy) or treatment (e.g. cryotherapy), reducing the potential for loss to follow-up in lower-resource settings. It uses liquid-based cytologic media and yields five separate results or channels: HPV16, HPV18/45, HPV 31/33/35/52/58, HPV51/59, HPV39/68/56/66 all with a corresponding cycle threshold.</description>
      <arm_group_label>Cervical cancer screening (single arm)</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Diagnostic Test</intervention_type>
      <intervention_name>S5 DNA methylation classifier</intervention_name>
      <description>The S5 classifier is a combination of DNA methylation levels of the late regions of the L1 and L2 proteins from HPV16, HPV18, HPV31, and HPV33, as well as DNA methylation of the promotor region of the human tumor suppressor gene, Erythrocyte Membrane Protein Band 4.1 Like 3 (EPB41L3).</description>
      <arm_group_label>Cervical cancer screening (single arm)</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria&#xD;
  &#xD;
            -  HIV-1 infection, as documented by 1) any FDA approved, licensed HIV rapid test&#xD;
               performed in conjunction with screening (oral immunoblot, enzyme-linked&#xD;
               immunoassay-ELISA, test kit, and confirmed by Western blot or other approved test), OR&#xD;
               2) a physician's written record that documents HIV infection with supporting&#xD;
               information on the participant's relevant medical history and/or current management of&#xD;
               HIV infection, OR 3) documentation of a prescription of an approved antiretroviral&#xD;
               regimen by either possession of pill bottles or packages with prescriber's name or&#xD;
               antiretrovirals (ARVs) dispensed from an HIV clinical treatment program with two&#xD;
               participant identifiers affixed to the bottles or packages.&#xD;
  &#xD;
            -  Cisgender women or transgender men.&#xD;
  &#xD;
            -  Aged 25 to 65.&#xD;
  &#xD;
            -  Ability to understand and the willingness to sign a written informed consent document&#xD;
               by the participant or by the legal representative(s) of the participant.&#xD;
  &#xD;
          Exclusion Criteria&#xD;
  &#xD;
            -  History of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer.&#xD;
  &#xD;
            -  Have undergone cervical cancer screening in the last 6 months.&#xD;
  &#xD;
            -  Have undergone cervical HSIL treatment in the past year.&#xD;
  &#xD;
            -  Have a history of hysterectomy with removal of the cervix.&#xD;
  &#xD;
            -  Have never had sexual intercourse (oral or genital or anal).&#xD;
  &#xD;
            -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
               infection (including opportunistic infections of Acquired Immunodeficiency&#xD;
               Syndrome-AIDS and/or genitourinary infections), symptomatic congestive heart failure,&#xD;
               unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations&#xD;
               that would limit compliance with study requirements.&#xD;
  &#xD;
            -  Pregnant women are excluded from this study due to the lack of safety data of&#xD;
               performing colposcopy during pregnancy.&#xD;
  &#xD;
            -  Any other medical condition or social situation that would put the participant, the&#xD;
               study staff, or the study outcomes at risk, as determined by the site investigators.&#xD;
        </textblock>
      </criteria>
      <gender>Female</gender>
      <gender_based>Yes</gender_based>
      <gender_description>The study will enroll cisgender women and transgender men.</gender_description>
      <minimum_age>25 Years</minimum_age>
      <maximum_age>65 Years</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Timothy Wilkin, MD, MPH</last_name>
      <role>Study Chair</role>
      <affiliation>Weill Medical College of Cornell University</affiliation>
    </overall_official>
    <overall_official>
      <last_name>Grant Ellsworth, MD, MS</last_name>
      <role>Principal Investigator</role>
      <affiliation>Weill Medical College of Cornell University</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Caíque Mello, MPH</last_name>
      <phone>212-746-7204</phone>
      <email>cam2358@med.cornell.edu</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Glenn Sturge</last_name>
      <email>gls2003@med.cornell.edu</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>University of São Paulo</name>
        <address>
          <city>São Paulo</city>
          <zip>05403-911</zip>
          <country>Brazil</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Lenice Galan de Paula</last_name>
        <phone>55-11-2661-7554</phone>
        <email>lenice.galan@hc.fm.usp.br</email>
      </contact>
      <investigator>
        <last_name>Luisa L Villa, PhD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location>
      <facility>
        <name>National Institute of Public Health, Mexico</name>
        <address>
          <city>Cuernavaca</city>
          <state>Morelos</state>
          <zip>62209</zip>
          <country>Mexico</country>
        </address>
      </facility>
      <status>Not yet recruiting</status>
      <contact>
        <last_name>Alejandra J Portillo Romero, MD</last_name>
        <email>alejandra.portillo@insp.mx</email>
      </contact>
      <investigator>
        <last_name>Eduardo C Lazcano Ponce, MD</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>Brazil</country>
      <country>Mexico</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 14, 2023</study_first_submitted>
    <study_first_submitted_qc>August 14, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 21, 2023</study_first_posted>
    <last_update_submitted>August 14, 2023</last_update_submitted>
    <last_update_submitted_qc>August 14, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 21, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>HPV</keyword>
    <keyword>cervical cancer screening</keyword>
    <keyword>women with HIV</keyword>
    <keyword>DNA methylation</keyword>
    <keyword>extended HPV genotyping</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Infections</mesh_term>
      <mesh_term>Communicable Diseases</mesh_term>
      <mesh_term>Papillomavirus Infections</mesh_term>
      <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Yes</sharing_ipd>
      <ipd_description>Individual participant data that underlie results in the publication, after deidentification</ipd_description>
      <ipd_info_type>Study Protocol</ipd_info_type>
      <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
      <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
      <ipd_time_frame>3 months post-publication of the primary manuscript through the duration of the NIH award (U54242639).</ipd_time_frame>
      <ipd_access_criteria>Researchers who provide a methodologically sound proposal for use of the data that is approved by the study investigators and the sponsor.&#xD;
  The research must be broadly consistent with that of ULACNet.&#xD;
  Researchers may submit a request to the study principal investigator (Timothy Wilkin tiw2001@med.cornell.edu) to request details of request format</ipd_access_criteria>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06002126
  org study id: 23-02025683
  secondary id: U54CA242639
  nct id: NCT06002126
  lead sponsor: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: No
  is fda regulated device: No
  Cervical cancer is a relatively common cancer among women living with human immunodeficiency
        virus (HIV). This study will test women for human papillomavirus (HPV) infection of the
        cervix. The main purpose of this study is to determine the best way to test for damaged areas
        of the cervix. Damaged areas of the cervix should be treated and removed to prevent cancer of
        the cervix.
  
        Women in this study will be seen once, twice or three times in a year. Women will provide
        several samples related to screening for cervical cancer including a swab of the cervix, a
        self-collected swab of the vagina and urine. Women will have a detailed examination of the
        cervix called colposcopy and have a few biopsies, or small pinches of the cervix, to look for
        areas at risk for turning into cancer. If HPV of the cervix is found but treatment of the
        cervix is not indicated, women will return in 6 months and in 12 months to repeat these
        tests. Most women will only need 1 visit. Women found to have damaged areas of the cervix at
        risk for turning into cancer will be referred for treatment.
  
        This protocol will compare different tests to understand the best test to identify women at
        risk for cervical cancer.
  The overall goal of this research is to develop a point of care high-risk HPV (hrHPV) test
        and molecular testing that optimizes specificity to detect high-grade squamous
        intraepithelial lesions (HSIL), specifically cervical intraepithelial neoplasia of grade 2 or
        more (CIN 2+), in women living with HIV (WHIV) in Latin America while maintaining high test
        sensitivity. To accomplish this goal, the protocol will optimize cervical screening by
        modifying the cycle threshold/genotype interpretation of Xpert HPV assay output. In a
        secondary manner, the protocol will also evaluate whether triage with HPV/host DNA
        methylation improves the specificity of Xpert alone.
  
        The hypotheses for this protocol includes:
  
        • The Xpert HPV test can be optimized for HSIL detection (CIN2+) in WHIV to significantly
        improve test specificity, when compared to unmodified test output using manufacturer
        guidelines.
  
        To evaluate this hypothesis, the protocol will enroll 1000 cisgender women or transgender men
        age 25-65 years living with HIV who are undergoing routine cervical cancer screening. These
        individuals will be recruited from affiliated clinical sites of the National Institute of
        Public Health in Cuernavaca, Mexico and University of São Paulo, Brazil. Participants will
        provide a first void urine sample and will be instructed how to self-collect a vaginal swab.
        An oral gargle specimen will be collected for HPV testing, HPV methylation, and Epstein-Bar
        Virus (EBV) co-infection. They will receive a baseline questionnaire about risk factors for
        HPV and cervical cancer, and provide a blood specimen for CD4 count, plasma viral load, DNA
        methylation of biological aging, circulating tumor HPV DNA (ctHPVDNA) analysis, and stored
        sera. Next, a provider will collect an anal swab. Then the participant will undergo a
        speculum exam and a provider will collect a cervical cytobroom sample for cytology and HPV
        testing followed by a swab for stored specimens. Finally, acetic acid will be applied
        followed by a digital image of the cervix. Then at least two cervical biopsies will be
        obtained.
  
        Material from one provider-collected cervical swab will undergo cervical cytology assessment
        using Bethesda Criteria. Cervical histology results from the collected biopsies will be
        interpreted according to the Lower Anogenital Squamous Terminology (LAST). HSIL will be
        defined as CIN 2 with diffuse p16 staining, CIN 2-3, or CIN 3. Women diagnosed with HSIL will
        be treated according to local standards. The local histology result will be used for the
        management of participants. Any lesions suspicious for invasive cancer will be referred to
        the appropriate specialist. Women with HSIL on cytology, but no HSIL on histology will be
        treated according to the local standard. The management options include repeat colposcopy,
        endocervical curettage, or a diagnostic loop electro-excision procedure. Similarly, women
        with a Type 3 transformation zone should have endocervical curettage and be managed according
        to local standards. After local pathology review, all histology specimens will be shipped
        centrally for Histology Endpoint Adjudication; these adjudicated histology results will be
        used for reporting research findings. The details of this process will be in the Manual of
        Procedures. Discordance between the local and central pathology review will be adjudicated
        with a second central pathologist. The final histology result will be sent back to the local
        site and provided to the participant and their providers. Women found to have vulvar, vaginal
        or perianal lesions suspicious for HSIL will be referred for appropriate evaluation.
  
        The self-collected vaginal swab and material from the provider-collected cytobroom sample
        will be tested for HPV using Xpert HPV. Xpert testing of self- and provider-collected samples
        will be conducted locally (at the point of care) in Brazil and Mexico. Remaining material
        from the vaginal and cervical samples will be shipped to Dr. Villa's lab in Brazil to allow
        for S5 methylation testing of any WHIV with hrHPV detected. Residual samples, as well as the
        collected urine, will be stored in Dr. Villa's lab for future studies.
  
        Women with hrHPV detected on a provider-collected cervical sample using a locally available
        and approved test, but who were negative for HSIL as determined by cervical biopsy, will be
        asked to return for a follow-up study visit at 6-month to receive the same procedures
        described above (with the exception of blood draws). If at the 6-month follow-up visit WHIV
        continue to have detection of hrHPV, but are HSIL negative by biopsy, they will be asked to
        return for an additional follow-up study visit 6 months later (12-months post-baseline) to
        receive the same procedures. We estimate that approximately 40% of the population will have
        hrHPV detected and may need to return for a follow-up visit; and 7% will be HSIL+ and
        referred for treatment.
  allocation: N/A
  intervention model: Single Group Assignment
  primary purpose: Diagnostic
  masking: None (Open Label)
  measure: Number of participants with cervical HSIL or invasive cancer on histology at baseline
  time frame: Baseline
  description: Cervical HSIL is defined as cervical intraepithelial neoplasia (CIN) 2 with p16 staining, CIN2-3, or CIN3) or squamous cell carcinoma from histology of cervical biopsies
  measure: Number of participants with hrHPV at baseline who are found to have cervical HSIL or invasive cancer on histology at months 6 or 12
  time frame: Month 6 or month 12
  description: Cervical HSIL is defined as cervical intraepithelial neoplasia (CIN) 2 with p16 staining, CIN2-3, or CIN3) or squamous cell carcinoma from histology of cervical biopsies.
  Only those subjects that had detection of hrHPV in cervical or vaginal specimens at the baseline or 6 month visit will be included in the count.
  arm group label: Cervical cancer screening (single arm)
  arm group type: Experimental
  description: Women will be screened for cervical cancer with HPV testing that provides extended genotyping and DNA quantification. Women will also provide other samples for cervical cancer screening tests. Women will under cervical biopsies.
  intervention type: Diagnostic Test
  intervention name: Xpert HPV
  description: The Cepheid Xpert HPV Assay (Xpert HPV) is a qualitative, real-time polymerase chain reaction (PCR) assay for the detection of hrHPV DNA. The assay is formatted in a single-use, Xpert HPV test cartridge and is run on the Cepheid Xpert® System, a multi-analyte, random access, molecular-diagnostic platform ranging in capacity from 1 to 80 test processing modules. Importantly, a single hrHPV DNA test can be completed in one hour, permitting same-day screening and diagnosis (e.g. colposcopy) or treatment (e.g. cryotherapy), reducing the potential for loss to follow-up in lower-resource settings. It uses liquid-based cytologic media and yields five separate results or channels: HPV16, HPV18/45, HPV 31/33/35/52/58, HPV51/59, HPV39/68/56/66 all with a corresponding cycle threshold.
  arm group label: Cervical cancer screening (single arm)
  intervention type: Diagnostic Test
  intervention name: S5 DNA methylation classifier
  description: The S5 classifier is a combination of DNA methylation levels of the late regions of the L1 and L2 proteins from HPV16, HPV18, HPV31, and HPV33, as well as DNA methylation of the promotor region of the human tumor suppressor gene, Erythrocyte Membrane Protein Band 4.1 Like 3 (EPB41L3).
  arm group label: Cervical cancer screening (single arm)
  criteria: 
  gender: Female
  gender based: Yes
  gender description: The study will enroll cisgender women and transgender men.
  minimum age: 25 Years
  maximum age: 65 Years
  healthy volunteers: No
  last name: Timothy Wilkin, MD, MPH
  role: Study Chair
  affiliation: Weill Medical College of Cornell University
  last name: Grant Ellsworth, MD, MS
  role: Principal Investigator
  affiliation: Weill Medical College of Cornell University
  last name: Caíque Mello, MPH
  phone: 212-746-7204
  email: cam2358@med.cornell.edu
  last name: Glenn Sturge
  email: gls2003@med.cornell.edu
  facility: 
  status: Recruiting
  contact: 
  investigator: 
  facility: 
  status: Not yet recruiting
  contact: 
  investigator: 
  country: Brazil
  country: Mexico
  responsible party type: Sponsor
  mesh term: Infections
  mesh term: Communicable Diseases
  mesh term: Papillomavirus Infections
  mesh term: Uterine Cervical Neoplasms
  sharing ipd: Yes
  ipd description: Individual participant data that underlie results in the publication, after deidentification
  ipd info type: Study Protocol
  ipd info type: Statistical Analysis Plan (SAP)
  ipd info type: Informed Consent Form (ICF)
  ipd time frame: 3 months post-publication of the primary manuscript through the duration of the NIH award (U54242639).
  ipd access criteria: Researchers who provide a methodologically sound proposal for use of the data that is approved by the study investigators and the sponsor.
  The research must be broadly consistent with that of ULACNet.
  Researchers may submit a request to the study principal investigator (Timothy Wilkin tiw2001@med.cornell.edu) to request details of request format